Pharmaceuticals major Zydus Cadila has received permission from the Subject Expert Committee (SEC) to conduct clinical trials of its monoclonal antibodies (mAbs) based cocktail for the treatment of Covid-19. Zydus said that the monoclonal antibody cocktail ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies, has been found to be safe and well-tolerated in animal toxicology studies and has displayed the ability to counterbalance SARS-CoV-2 both in vitro and in animal studies.

ZRC-3308 is a cocktail of two anti-SARS-CoV-2 monoclonal antibodies. The monoclonal antibodies of ZRC-3308 have been specifically designed to provide protection for a much longer period of time than the currently approved products, the company claims. After the development, Zydus has become the only Indian company to get the nod from the Central Drugs Standard Control Organisation’s SEC for the trials of its antibodies cocktail.

• Tata Power Inks MoU with Asian Development Bank for $4.25 Billion 
• Innovators Facade Shares Skyrocketed 11% on Securing Orders Worth Rs 110 Crore 
• Stocks in Focus: SJVN, Tata Power, Afcons Infrastructure, and Others
• Stocks Under F&O Ban: Adani Enterprises, Aarti Industries, Indraprastha Gas, and Others 
• RBI Defends Currency Moves to Protect Economy

While applying for the permission, the company had claimed that the cocktail can come out as one of the main treatments for mild Covid-19. Zydus further said, “SARS-CoV-2 spike protein targeted, neutralizing monoclonal antibody-based treatments have received emergency use authorization in mild Covid-19 in the US, Europe and in India because they significantly reduced viral load in mild patients and their rate of hospitalization.”